388 completed, 129 unknown, 69 terminated, 53 recruiting. 727 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 727 | Completed 388, Unknown 129, Terminated 69, Recruiting 53, Withdrawn 37, Not yet recruiting 23, Active not recruiting 20, Enrolling by invitation 4, Suspended 4 |
Follow Renal Insufficiency: new trials by email Literature Review of Renal Insufficiency trials Research Report on Renal Insufficiency
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant Access Semaglutide, Virtual Weight Management Coaching - Obesity, Chronic Kidney Disease | Phase 4 | Not yet recruiting | Kristin Clemens | 880 | 2027-01-01 | 2026-10-05 |
| Heart-Kidney-Diabetes Multidisciplinary Care MOdels for CardiovascuLar Health In Patients With Chronic Kidney DiSease and Diabetes: A PragmaTIC Cluster Randomized Controlled Trial (HOLISTIC) The intervention with the MCM is Kidney-Heart GDMT initiation and titration for dose optimization (as clinically tolerated), within 4 months of enrollment in the study. - Chronic Kidney Disease, Type II Diabetes | Phase 4 | Not yet recruiting | Baim Institute for Clinical Research | 570 | 2026-12-01 | 2026-09-10 |
| Study on the Safety and Efficacy of a Time-of-Day-Based Individualized Tacrolimus Dosing Regimen in Kidney Transplant Recipients Chronotherapy-based individualized low-morning high-evening tacrolimus dosing, conventional dosing regimen - End-Stage Renal Disease | Phase 4 | Not yet recruiting | The First Affiliated Hospital of Guangzhou Medical University | 100 | 2026-10-25 | 2026-10-16 |
| A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China Semaglutide - Cardiovascular Risk, Chronic Kidney Disease | Phase 4 | Recruiting | Novo Nordisk A/S | 300 | 2026-10-12 | 2026-10-28 |
| Role of Finerenone in African American Veterans With Diabetic Kidney Disease Finerenone 10 MG, Empagliflozin 10 MG - Diabetic Kidney Disease | Phase 4 | Not yet recruiting | Washington D.C. Veterans Affairs Medical Center | 30 | 2026-10-01 | 2026-08-21 |
| Amino Acid Infusion in Cardiac Surgery Travesol 10% - Acute Kidney Injury, Cardiac Surgery | Phase 4 | Not yet recruiting | Milton S. Hershey Medical Center | 130 | 2026-10-01 | 2026-05-13 |
| Infliximab for Immune Checkpoint Inhibitor Associated AKI Infliximab, Prednisone, prednisone (oral) - Acute Kidney Injury, Acute Interstitial Nephritis | Phase 4 | Recruiting | Massachusetts General Hospital | 44 | 2026-09-15 | 2026-10-09 |
| A Prompt REstart Study of Renin-Angiotensin System Inhibitors After Acute Kidney Injury Early RASi restart strategy, Usual Care - Acute Kidney Injury | Phase 4 | Recruiting | University of California, San Francisco | 60 | 2026-09-01 | 2026-09-08 |
| Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2 Empagliflozin 10 MG then Placebo, Placebo then Empagliflozin 10 MG - Chronic Kidney Diseases | Phase 4 | Recruiting | Centre Hospitalier Universitaire de Nice | 34 | 2026-08-25 | 2026-09-10 |
| The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS) Piperacillin + Tazobactam, meropenem - Infection, Acute Kidney Injury | Phase 4 | Recruiting | Bassett Healthcare | 852 | 2026-08-17 | 2026-10-15 |
| Effect of Secukinumab on Cardiorenal Outcomes in Patients With Cardiorenal Metabolic Syndrome and Atherosclerotic Cardiovascular Disease Secukinumab (75 mg), Standard Medical Therapy - Cardiorenal Metabolic Syndrome, Atherosclerotic Cardiovascular Disease | Phase 4 | Not yet recruiting | Peking University Third Hospital | 100 | 2026-07-15 | 2026-07-15 |
| Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease Finerenone (BAY 94-8862), Placebo - Albuminuria, Type 2 Diabetes Mellitus (T2DM) | Phase 4 | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 148 | 2026-07-01 | 2026-06-25 |
| Anrikefon vs Nalfurafine for Sleep Quality in Hemodialysis Patients With CKD-aP Anrikefon, Nalfurafine - Pruritus Chronic, Kidney Diseases, Chronic | Phase 4 | Recruiting | Zhujiang Hospital | 50 | 2026-06-22 | 2026-08-25 |
| Nafamostat Mesylate Versus Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Sepsis-Associated Acute Kidney Injury Citrate anticoagulation, Nafamostat Mesylate - Sepsis, Acute Kidney Injury | Phase 4 | Not yet recruiting | Jianfeng Xie | 1162 | 2026-06-10 | 2026-06-03 |
| mGFR vs tGFR in AKI transdermal GFR - AKI, GFR | Phase 4 | Not yet recruiting | Bin Du | 50 | 2026-06-08 | 2026-06-10 |
| CANagliflozin In DIALysis Patients Invokana 300 mg and 100 mg tablet - Dialysis, Chronic Kidney Disease (Stages 4 and 5) | Phase 4 | Not yet recruiting | University Medical Center Groningen | 10 | 2026-06-01 | 2026-05-06 |
| Sodium Bicarbonate for Critically Ill Patients With Metabolic Acidosis and Acute Kidney Injury Sodium Bicarbonate 8.4% Solution for Injection, Balanced crystalloid solution - Acute Kidney Injury, Metabolic Acidosis | Phase 4 | Recruiting | Universität Münster | 660 | 2026-05-07 | 2026-09-04 |
| rhBNP for Prevention of Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) Recombinant Human Brain Natriuretic Peptide (rhBNP), Normal Saline (Placebo) - AKI - Acute Kidney Injury, Cardiac Surgical Procedures | Phase 4 | Not yet recruiting | China National Center for Cardiovascular Diseases | 694 | 2026-05-01 | 2026-06-01 |
| Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease Dulaglutide, SGLT2i, Finerenone - T2DM (Type 2 Diabetes Mellitus), CKD - Chronic Kidney Disease | Phase 4 | Not yet recruiting | First Affiliated Hospital of Wannan Medical College | 468 | 2026-05-01 | 2026-04-22 |
| Amino Acid (15) Peritoneal Dialysis Solution for Nutritional Improvement in Peritoneal Dialysis Patients amino acid (15) peritoneal dialysis solution - End-stage Renal Disease (ESRD), Peritoneal Dialysis (PD) | Phase 4 | Enrolling by invitation | Shanghai 10th People's Hospital | 50 | 2026-05-01 | 2026-04-28 |
Showing 20 of 727. Sign in to see all of them.
Renal Insufficiency, Chronic (313) · Kidney Failure, Chronic (236) · Acute Kidney Injury (107) · Anemia (41) · Diabetes Mellitus, Type 2 (36) · Hypertension (33) · Diabetes Mellitus (28) · Kidney Diseases (28) · Proteinuria (28) · Cardiovascular Diseases (26) · Hyperparathyroidism, Secondary (22) · Heart Failure (16) · Anemia, Iron-Deficiency (13) · Coronary Artery Disease (13)
Female Urogenital Diseases (727) · Female Urogenital Diseases and Pregnancy Complications (727) · Male Urogenital Diseases (727) · Urogenital Diseases (727) · Urologic Diseases (726) · Kidney Diseases (699) · Pathological Conditions, Signs and Symptoms (560) · Pathologic Processes (552) · Disease Attributes (528) · Chronic Disease (522) · Renal Insufficiency, Chronic (208) · Nutritional and Metabolic Diseases (149) · Metabolic Diseases (135) · Cardiovascular Diseases (108)
Tacrolimus (23) · Mycophenolic Acid (20) · paricalcitol (19) · Saline Solution (18) · dapagliflozin (18) · empagliflozin (17) · Calcitriol (14) · Spironolactone (14) · Furosemide (12) · Sirolimus (12) · finerenone (12) · Darbepoetin alfa (11) · iodixanol (11) · Cinacalcet (10) · Cyclosporine (10)
Amgen (14) · Chinese University of Hong Kong (13) · National Taiwan University Hospital (10) · Yonsei University (10) · Wyeth is now a wholly owned subsidiary of Pfizer (9) · Seoul National University Hospital (8) · Abbott (7) · Massachusetts General Hospital (7) · Mahidol University (6) · University of Sao Paulo General Hospital (6) · Chinese PLA General Hospital (5) · GE Healthcare (5) · Indiana University (5) · Medical University of Vienna (5) · University Medical Center Groningen (5)
United States (180) · China (67) · South Korea (49) · Canada (36) · Italy (32) · Spain (29) · France (27) · Germany (27) · Netherlands (24) · Brazil (23) · Denmark (22) · Taiwan (22) · Egypt (20) · Japan (19) · United Kingdom (19)
Erling B Pedersen, Professor (4) · Byung-Hee Oh, M.D., Ph.D. (3) · Cheuk Chun Szeto, MD (3) · Dong Sun, MD (3) · Duk-Hee Kang, MD. PhD. (3) · Raymond T Chung, MD (3) · Sabyasachi Sen, MD, PhD (3) · Sang-Ho Jo, M.D. (3) · Adel R. Rizkala, Pharm.D., MS (2) · Alexander Zarbock, MD (2)
PMID 33314078, PMID 38018702, PMID 35224730, PMID 36416787, PMID 33586138, PMID 36791280, PMID 40576086, PMID 34519356, PMID 18328118, PMID 32588430, PMID 33000470, PMID 34164803, PMID 34231877, PMID 37870148, PMID 38189593, PMID 38899545, PMID 39607014, PMID 40855136, PMID 10221490, PMID 10607766, PMID 10798738, PMID 11181474, PMID 11406727, PMID 11505124, PMID 11562419, PMID 11904577, PMID 12138146, PMID 12438948, PMID 12761269, PMID 15327406, PMID 15385656, PMID 15492943, PMID 15814548, PMID 16014059, PMID 16221223, PMID 16245247, PMID 16363316, PMID 16949481, PMID 17035697, PMID 17108343, PMID 17202417, PMID 17261652, PMID 17267740, PMID 17276178, PMID 17396118, PMID 17462550, PMID 17468488, PMID 17592099, PMID 17622274, PMID 17943084
2008 (6), 2023 (4), 2014 (3), 2016 (3), 2018 (3), 2025 (3), 2004 (2), 2009 (2), 1IK2CX002030-01 (1), 1IK2CX002368-01A1 (1), 2005 (1), 2015 (1), K23DK139456 (1), R01DK139484 (1), R01DK144161 (1)